



DEPARTMENT OF HEALTH & HUMAN SERVICES

National Institutes of Health
Bethesda, Maryland 20892

January 7, 2015

J. Donald Easton, M.D.
Clinical Professor
UCSF Department of Neurology
Sandler Neurosciences Center
675 Nelson Rising Lane
San Francisco, CA 94158-0663

Dear Dr. Easton:

I am writing to confirm that the NINDS-appointed Data and Safety Monitoring Board (DSMB) for your clinical trial, "Platelet-Oriented Inhibition in New TIA and minor ischemic stroke" (POINT), met by teleconference on December 8, 2014 to review all interim data from the trial. The DSMB did not identify any concerns regarding safety or study implementation, and thus recommended the study proceed as planned.

The DSMB will meet in approximately six months to perform the next interim review.

Sincerely,

A handwritten signature in black ink, appearing to read "Peter R. Gilbert".

Peter R. Gilbert, Sc.M.
Clinical Research Project Manager
Office of Clinical Research
National Institute of Neurological Disorders and Stroke
National Institutes of Health
6001 Executive Boulevard, Suite 2202
Bethesda, MD 20892-9525